"Hans Berger" Klinik für Neurologie, Universitätsklinik Jena, An der Klinik 1, D-07747 Jena, Germany.
AMEOS Klinikum St. Clemens Oberhausen, Wilhelmstrasse 34, D-46145 Oberhausen, Germany.
Brain Res. 2020 Nov 15;1747:147033. doi: 10.1016/j.brainres.2020.147033. Epub 2020 Jul 28.
Anti-NMDA receptor encephalitis was first described about thirteen years ago and has become one of the most important differential diagnoses for new-onset psychosis. The disease is mediated by autoantibodies against the subunit 1 of the N-methyl-D-aspartate receptor (NMDA-R1) in patients presenting with variable clinical symptoms. Patients often profit from immunmodulatory therapy, independent of their individual symptoms. In this study CSF samples as well as monoclonal antibodies derived from patients diagnosed with NMDA-R1 encephalitis were applied to rat hippocampus and visualized by immunocytochemistry. This reveals at least two distinct patterns of immunoreactivity. Antibodies from "pattern group 1" display the familiar pattern of NMDA-R1 distribution in the hippocampus reported in experiments with rabbit anti-NMDA-R1 antibodies. Neurons and primary dendrites in the CA1 and CA3 region show strongly stained cell bodies, in line with the predominant postsynaptic localization of the NMDA receptor in the brain. However, autoantibodies from "pattern group 2" show an inverse pattern, with no staining of the cell bodies and primary dendrites in CA1 and CA3 regions. Electron microscopic experiments disclose that autoantibodies of "pattern group 1 patients" bind to postsynaptic NMDA receptors, while those of "pattern group 2 patients" target presynaptic NMDA receptors. We describe one NMDA-receptor antibody giving staining comparable to rabbit anti-NMDA-R1 antibodies, raised against the C-terminus. In the highly heterogenous disease anti-NMDA-receptor 1 encephalitis we found evidence for at least two different subtypes. It will be very interesting to determine whether there also are two distinct clinical phenotypes.
抗 N- 甲基-D- 天冬氨酸受体脑炎大约在十三年前首次被描述,已成为新发精神病的最重要鉴别诊断之一。该疾病由患者体内针对 N- 甲基-D- 天冬氨酸受体(NMDA-R1)亚单位 1 的自身抗体介导,患者表现出不同的临床症状。患者通常受益于免疫调节治疗,而与个体症状无关。在这项研究中,应用脑脊液样本和源自 NMDA-R1 脑炎患者的单克隆抗体,对大鼠海马体进行了免疫细胞化学染色。结果显示,至少存在两种不同的免疫反应模式。来自“模式组 1”的抗体显示了在兔抗 NMDA-R1 抗体实验中报道的 NMDA-R1 在海马体中的典型分布模式。CA1 和 CA3 区的神经元和初级树突表现出强烈染色的细胞体,符合 NMDA 受体在大脑中的主要突触后定位。然而,来自“模式组 2”的自身抗体显示出相反的模式,CA1 和 CA3 区的细胞体和初级树突没有染色。电镜实验显示,“模式组 1 患者”的自身抗体结合突触后 NMDA 受体,而“模式组 2 患者”的自身抗体则针对突触前 NMDA 受体。我们描述了一种 NMDA 受体抗体,其染色与针对 C 末端的兔抗 NMDA-R1 抗体相当。在高度异质性的抗 NMDA-R1 脑炎中,我们发现了至少两种不同亚型的证据。确定是否存在两种不同的临床表型将非常有趣。